@ha.dley's Zepbound journey, fact-checked
Quick answer
Tirzepatide (Zepbound) is a dual GIP/GLP-1 receptor agonist approved for chronic weight management. In the SURMOUNT-1 trial, participants achieved an average 20.9% body weight reduction at 72 weeks on the highest 15mg dose.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
TikTok creator @ha.dley shared her 10-month weight loss journey on Zepbound (tirzepatide), showing what appears to be significant physical changes in a before-and-after comparison. While she doesn't make explicit medical claims in this particular video, her transformation matches what clinical trials show about tirzepatide's effects.
What does this video actually claim?
The video shows @ha.dley's physical transformation after 10 months on Zepbound, though she originally planned to wait a full year before posting. She doesn't state specific numbers or make direct medical claims in this post.
The visual comparison suggests substantial weight loss over the 10-month period. Her caption focuses on the practical frustration of losing TikTok drafts when switching phones rather than making bold promises about the medication.
By using hashtags like #zepboundjourney and #weightlosstransformation, she's positioning her experience within the broader social media conversation about GLP-1 medications for weight management.
Does her timeline match what studies show?
Her 10-month timeline falls within the range of major tirzepatide trials, though peak effects typically occur earlier. The SURMOUNT-1 trial (Jastreboff et al., NEJM, 2022) tracked participants for 72 weeks, finding maximum weight loss around 60-68 weeks.
At 10 months (roughly 40 weeks), participants in SURMOUNT-1 had already achieved most of their eventual weight loss. Those on the highest 15mg dose averaged 20.9% body weight reduction by 72 weeks.
The visual change @ha.dley shows could reasonably align with these trial results, though individual responses vary significantly. Some people plateau earlier, others continue losing weight past the one-year mark.
What context is missing from her post?
While @ha.dley doesn't make false claims, her post lacks important context about tirzepatide treatment. She doesn't mention the medication's side effects, which affected 89% of participants in SURMOUNT-1.
The most common issues include nausea (experienced by 43% of participants), diarrhea (23%), and constipation (24%). About 16% of people discontinued treatment due to side effects.
Her transformation also doesn't address the lifestyle changes that typically accompany successful GLP-1 treatment. The trials combined medication with reduced-calorie diets and exercise counseling, not medication alone.
Is this typical for Zepbound users?
@ha.dley's apparent results fall within the range seen in clinical trials, though we can't verify her specific weight loss percentage from the video alone. In SURMOUNT-1, individual results varied widely even on the same dose.
About 91% of participants lost at least 5% of their body weight, while 57% achieved 20% or greater weight loss on the highest dose. This wide range means some people see dramatic changes like @ha.dley appears to show, while others see more modest results.
Her experience represents one data point, not a guarantee of typical results. The trial data provides a better sense of what most people can expect than any single social media post.
What should potential users know?
Tirzepatide (Zepbound) is FDA-approved for chronic weight management in adults with obesity or overweight with related health conditions. The medication requires a prescription and ongoing medical supervision.
Treatment typically starts at 2.5mg weekly, increasing gradually to minimize side effects. The maintenance dose ranges from 5mg to 15mg weekly, depending on individual response and tolerance.
Cost remains a significant barrier. Without insurance coverage, Zepbound can cost over $1,000 monthly. Insurance approval often requires meeting specific BMI criteria and having weight-related health conditions.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Compounded Tirzepatide access requires the right clinical path
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 6 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For @ha.dley's Zepbound journey, fact-checked, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Tirzepatide Once Weekly for the Treatment of Obesity
Primary SURMOUNT-1 trial source for tirzepatide weight-loss ranges and tolerability.
PubMed
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction
Used for continuation, stopping, and maintenance questions after initial weight loss.
PubMed
Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference
A broad meta-analysis anchor for GLP-1 weight-loss effect and class-level comparisons.
PubMed
Discontinuing glucagon-like peptide-1 receptor agonists and body habitus
Used for pages discussing stopping therapy, weight regain, and long-term planning.
PubMed
Video claim decision path
Turn the claim into a safer next question
Direct answer
Compounded Tirzepatide should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.
Evidence check
Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.
Safety check
A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.
Next step
Use the health tools and supporting evidence to prepare questions for your clinician.
Claim path
Keep researching this tirzepatide video claims cluster
Best for searchers deciding whether tirzepatide claims are stronger, safer, or more relevant than semaglutide claims.
Claim verdict
The useful answer behind this video
Claim being checked
Tirzepatide (Zepbound) is a dual GIP/GLP-1 receptor agonist approved for chronic weight management.
FormBlends verdict
Tirzepatide (Zepbound) is a dual GIP/GLP-1 receptor agonist approved for chronic weight management. In the SURMOUNT-1 trial, participants achieved an average 20.9% body weight reduction at 72 weeks on the highest 15mg dose.
Patient-safe next step
Compare the claim with the Compounded Tirzepatide guide, safety notes, access rules, and a licensed-provider review.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- Tirzepatide (Zepbound) is a dual GIP/GLP-1 receptor agonist approved for chronic weight management. In the SURMOUNT-1 trial, participants achieved an average 20.9% body weight reduction at 72 weeks on the highest 15mg dose.
- Tirzepatide achieved 20.9% average weight loss at 72 weeks in the SURMOUNT-1 trial
- @ha.dley's 10-month timeline matches when most participants saw peak effects in clinical studies
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compounded Tirzepatide decisions still need source quality, legal access, and provider oversight checks.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against the Compounded Tirzepatide guide, cost path, safety notes, and provider review before acting.
Review Compounded TirzepatideWhat You'll Learn
- Tirzepatide achieved 20.9% average weight loss at 72 weeks in the SURMOUNT-1 trial
- @ha.dley's 10-month timeline matches when most participants saw peak effects in clinical studies
- 89% of trial participants experienced side effects, most commonly nausea, diarrhea, and constipation
- Individual results varied widely in trials, from minimal loss to over 25% body weight reduction
- 16% of participants discontinued treatment due to side effects in major trials
- Zepbound requires prescription supervision and can cost over $1,000 monthly without insurance
- Clinical trials combined medication with reduced-calorie diets and exercise counseling
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Hadley | Spine Healing Era · TikTok creator
19.5K views on this video
i was planning to post this after 1 full year on zepbound but i got a new phone and tiktok drafts don’t transfer :( so here’s 10 months! #zepbound #zepboundjourney #zepboundcommunity #weightloss #we
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Hadley | Spine Healing Era, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.